Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy

P. B. Chretien, S. D. Lipson, R. Makuch, D. E. Kenady, M. H. Cohen, J. D. Minna

Research output: Contribution to journalArticle

40 Scopus citations

Abstract

Studies on the effect of thymosin on T-cell levels in vitro among normal persons and cancer patients show that, in general, T-cell levels increase after incubation with thymosin in populations with low initial T-cell levels while the levels decrease in populations with high initial T-cell levels. In patients with small cell carcinoma of the lung receiving intensive chemotherapy also randomized to receive thymosin at a dose of 60 mg/m 2, thymosin at a dose of 20 mg/m 2, or placebo twice weekly, increased survival occurred in patients receiving the thymosin dose of 60 mg/m 2. The increase in survival was greatest in patients with low pretreatment T-cell and α 2HS-glycoprotein levels. These observations suggest that the cancer patients most likely to benefit therapeutically from adjuvant treatment with thymosin are those with relatively low initial T-cell levels and other parameters of cellular immunity.

Original languageEnglish (US)
Pages (from-to)1787-1790
Number of pages4
JournalCancer Treatment Reports
Volume62
Issue number11
StatePublished - Dec 1 1978

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy'. Together they form a unique fingerprint.

  • Cite this

    Chretien, P. B., Lipson, S. D., Makuch, R., Kenady, D. E., Cohen, M. H., & Minna, J. D. (1978). Thymosin in cancer patients: In vitro effects and correlations with clinical response to thymosin immunotherapy. Cancer Treatment Reports, 62(11), 1787-1790.